Different kinetic patterns of BCR‐ABL transcript levels in imatinib‐treated chronic myeloid leukemia patients after achieving complete cytogenetic response
Yazhen Qin,Yuanan Liu,Hong-Hu Zhu,Jie Li,G. Ruan,Youyi Zhang,Qian Jiang,Hao Jiang,Ling-di Li,Yingjun Chang,Xiao-jun Huang,Shan-shan Chen
DOI: https://doi.org/10.1111/j.1751-553X.2007.00962.x
2008-08-01
International Journal of Laboratory Hematology
Abstract:Bone marrow BCR‐ABL transcript levels were monitored serially by real‐time quantitative PCR in 46 imatinib‐treated chronic myeloid leukemia patients after achieving complete cytogenetic response (CCyR) for a median of 42 months (range: 9–53). Of 41 patients in continuous CCyR, 32 and nine could achieve a ≥3‐log (MMoR group) or 2‐ to 3‐log reduction (non‐MMoR group), respectively. The MMoR group had a significantly lower recurrence rate of Ph+ metaphase than the non‐MMoR group (6/32 vs. 7/9, P = 0.002), which was not significantly different between patients first achieving CCyR within or after 12 months of imatinib treatment (7/27 vs. 6/14, P = 0.086). Five patients suffered cytogenetic or hematological relapse. For all 46 patients, a >2‐log reduction but not time when CCyR was first achieved was related to a lower relapse rate (1/42 vs. 4/4, P < 0.001). We concluded that the depth of BCR‐ABL reduction after CCyR is more critical than when CCyR is first achieved. The kinetic pattern of BCR‐ABL transcript is a good predictor of disease stability.